RNA therapeutics companies develop medicines that use RNA molecules to alter protein production, silence disease-associated genes or deliver therapeutic instructions to cells. These approaches support the treatment of genetic disorders, cancer, infectious disease and other conditions.
This category includes companies working on:
Browse 48 UK RNA therapeutics companies below.
DNA nanorobot platform for nucleic acid detection and bioanalysis
Nanovery is a biotechnology company developing a patented Nucleic Acid Nanorobotics (NANs) platform for enzyme-free detection and quantification of nucleic acid targets. Synthetic…
Needle-free solid dose vaccine formulation and delivery platform
aVaxMed Limited is a UK biotech developing the aVaxziPen platform, a proprietary needle-free, thermally stable, solid dose vaccine delivery system. The technology encapsulates…
siRNA therapeutics targeting liver-expressed disease genes
Silence Therapeutics is a clinical-stage biotechnology company developing siRNA therapeutics using its proprietary platform. The platform enables precise silencing of…
RBC derived nanoparticles for RNA delivery to brain and immune cells
Crane Biosciences is a biotechnology company developing a non-immunogenic RNA delivery platform based on nanoparticles derived from red blood cell membranes. By using the body's…
Stem cell-derived exosome platform for targeted drug delivery
ReNeuron is a biotechnology company developing a stem cell-derived exosome platform for targeted therapeutic delivery. Founded on over two decades of stem cell science, including…
mRNA vaccine manufacturer and R&D partner
Moderna is a company developing and manufacturing mRNA-based medicines and vaccines across infectious disease, oncology and rare disease. Its UK Innovation and Technology Centre,…
Long-lasting RNA platform for cell engineering and therapy manufacture
Plurify is a biotech developing a long-lasting RNA platform that enables stable, non-integrating gene expression in cells for over 100 days without genomic integration. The system…
LNP-mRNA growth factor therapy to restore hearing loss
CamGene Therapeutics is a preclinical biotechnology company developing lipid nanoparticle-delivered mRNA medicines to treat hearing loss at its underlying cellular cause. Its lead…
European hub for RNAi therapeutics developer
Alnylam UK is the European operational headquarters of Alnylam Pharmaceuticals, the pioneer of RNA interference therapeutics. Based in Maidenhead, the UK office serves as…
RNA immunotherapies targeting novel tumour-specific antigens
Epitopea is a biopharma company developing off-the-shelf RNA-based immunotherapies for hard-to-treat cancers. Using spatial immunopeptidomics, genomics, and systems…
Non-viral intracellular drug delivery for solid tumours
Vitarka Therapeutics is a preclinical biotech company developing a non-viral drug delivery platform for targeted intracellular delivery of therapeutics to solid tumours. The…
AI drug discovery platform developing novel biologics for cancer and AMR
AMPLY Discovery is a biotechnology company developing an AI-driven drug discovery platform that combines machine learning, next-generation sequencing, and synthetic biology to…